Metraipolis › archive › dc_ae2b416145d1

Repurposing risperidone as an anti-angiogenic agent for triple-negative breast cancer: a computational to in ovo investigation — Europe PMC PMID:41229499

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41229499
DOI
10.3389/fonc.2025.1645905
License (as archived)
solo-consultazione
Archived
2026-11-09T00:24:43.055Z
SHA-256 of the archived text
39f4242e58d3c38f780b46e412588ecda2a4a4342aa659ddda0f35ec17765e4e
Stable URL of this page
https://metraipolis.com/documento/dc_ae2b416145d1

How to cite

Repurposing risperidone as an anti-angiogenic agent for triple-negative breast cancer: a computational to in ovo investigation — Europe PMC PMID:41229499 — Europe PMC (en), https://europepmc.org/article/MED/41229499 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ae2b416145d1 (Metraipolis archive dc_ae2b416145d1, sha256 39f4242e58d3c38f780b46e412588ecda2a4a4342aa659ddda0f35ec17765e4e)
BibTeX
@misc{dcae2b416145d1,
  title = {Repurposing risperidone as an anti-angiogenic agent for triple-negative breast cancer: a computational to in ovo investigation — Europe PMC PMID:41229499},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41229499},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ae2b416145d1; sha256 39f4242e58d3c38f780b46e412588ecda2a4a4342aa659ddda0f35ec17765e4e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41229499. Agents can read the archived copy with the MCP tool read_document.